Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis 

Published byShavonne Cox Modified over 7 years ago

Similar presentations

Presentation on theme: "Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis "— Presentation transcript:

1 Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis  Tingting Tao, Xuehua Jiang, Yuehong Chen, Yiran Song  International Journal of Infectious Diseases  Volume 55, Pages (February 2017) DOI: /j.ijid Copyright © 2017 The Authors Terms and Conditions

2 Figure 1 Flow diagram of study selection.
International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

3 Figure 2 Forest plot for SVR12 of LDV-SOF versus LDV-SOF+RBV therapy.
The central square of each horizontal line represents the RR for each study. The lines demonstrate the range of the 95% CI. The vertical line at an RR of 1 is the line of no effect. % Weight indicates the influence exerted by each study on the pooled RR. LDV=ledipasvir ; SOF=sofosbuvir; CI=confidence interval; M-H=Mantel-Haenszel. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

4 Figure 3 Forest plot of SVR12 based on different treatment durations.
International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

5 Figure 4 Forest plot of SVR12 based on different treatment history.
International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

6 Figure 5 Forest plot of SVR12 based on different HCV genotype.
International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

7 Figure 6 Forest plot of SVR12 based on different hepatic cirrhosis status. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

8 Figure 7 Forest plot for virologic breakthrough and relapse of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

9 Figure 8 Forest plot of virologic failure based on different treatment durations. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

10 Figure 9 Forest plot of virologic failure based on different treatment history. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

11 Figure 10 Forest plot of relapse based on different treatment durations. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

12 Figure 11 Forest plot of relapse based on different treatment history.
International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

13 Figure 12 Forest plot for the safety outcomes of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

14 Figure 13 Forest plot of discontinuation based on different treatment durations. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

15 Figure 14 Forest plot of discontinuation based on different treatment history. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

16 Figure 15 Forest plot of adverse events based on different treatment durations. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

17 Figure 16 Forest plot of adverse events based on different treatment history. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

18 Figure 17 Forest plot for the adverse events of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

19 Figure 17 Forest plot for the adverse events of LDV-SOF versus LDV-SOF+RBV therapy. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

20 Figure 18 Forest plot of serious adverse events based on different treatment durations. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

21 Figure 19 Forest plot of serious adverse events based on different treatment history. International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

22 Figure 20 Funnel plot of SVR12.
International Journal of Infectious Diseases  , 56-71DOI: ( /j.ijid ) Copyright © 2017 The Authors Terms and Conditions

Download ppt "Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis "

Similar presentations

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced HCV GT1 Retreatment of Sofosbuvir Failures Phase 2 Treatment.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir + RBV in Sofosbuvir-Experienced HCV GT1 Retreatment of Sofosbuvir Failures Phase 2 Treatment.
ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.

ARV-trial.com C-SWIFT Study: grazoprevir/elbasvir + SOF in genotypes 1 or 3, with or without cirrhosis Randomisation 1 : 1 Open-label Design W4 W6 W8.
ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.

ION-1  Design LDV/SOF LDV/SOF + RBV Randomisation* 1 : 1 : 1 : 1 Open-label ION-1 Study: LDV/SOF + RBV for genotype 1 W24W12 ≥ 18 years Chronic HCV infection.
> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.

> 18 years Chronic HCV infection Genotype 1 Failure (relapse) to 4, 6 or 8 weeks of GZR/EBR + SOF in C-SWIFT Part A Compensated cirrhosis assessed by liver.
Syndromic classification of rickettsioses: an approach for clinical practice Álvaro A. Faccini-Martínez, Lara García-Álvarez, Marylin Hidalgo, José A.

Syndromic classification of rickettsioses: an approach for clinical practice Álvaro A. Faccini-Martínez, Lara García-Álvarez, Marylin Hidalgo, José A.
Volume 16, Issue 6, Pages (September 2013)

Volume 16, Issue 6, Pages (September 2013)
Prognostic Value of Morning Blood Pressure Surge in Clinical Events: A Meta-analysis of Longitudinal Studies  Jun-Chao Xie, Han Yan, Yan-Xin Zhao, PhD,

Prognostic Value of Morning Blood Pressure Surge in Clinical Events: A Meta-analysis of Longitudinal Studies  Jun-Chao Xie, Han Yan, Yan-Xin Zhao, PhD,
Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study

Daclatasvir + Sofosbuvir in Genotype 3 ALLY-3 Study
Yun Hyung Koog, Jin Su Lee, Hyungsun Wi 

Yun Hyung Koog, Jin Su Lee, Hyungsun Wi 
Phase 3 Treatment-Naïve and Treatment-Experienced

Phase 3 Treatment-Naïve and Treatment-Experienced
Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review  X.-F. Gao, Z.-W. Yang, J. Li  International.

Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review  X.-F. Gao, Z.-W. Yang, J. Li  International.
Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother- to-child transmission—a meta-analysis  Zhongjie Shi, Xiaomao Li,

Hepatitis B immunoglobulin injection in pregnancy to interrupt hepatitis B virus mother- to-child transmission—a meta-analysis  Zhongjie Shi, Xiaomao Li,
Copyright © 2011 American Medical Association. All rights reserved.

Copyright © 2011 American Medical Association. All rights reserved.
HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?  Giuseppe Bruno, Annalisa.

HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?  Giuseppe Bruno, Annalisa.
Effectiveness of silver-impregnated central venous catheters for preventing catheter- related blood stream infections: a meta-analysis  Ya-Mei Chen, Ai-Ping.

Effectiveness of silver-impregnated central venous catheters for preventing catheter- related blood stream infections: a meta-analysis  Ya-Mei Chen, Ai-Ping.
Volume 149, Issue 6, Pages (November 2015)

Volume 149, Issue 6, Pages (November 2015)
Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.

Rapid virological response tailors the duration of treatment in hepatitis C virus genotype 3 patients treated with pegylated interferon alfa-2a and ribavirin.
Thomas F. O’Donnell, MD, Joseph Lau, MD  Journal of Vascular Surgery 

Thomas F. O’Donnell, MD, Joseph Lau, MD  Journal of Vascular Surgery 
Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.

Systematic Review of Controlled Clinical Trials on the Use of Ursodeoxycholic Acid for the Prevention of Hepatic Veno-occlusive Disease in Hematopoietic.
Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,

Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the ‘accordion’ regimen?  Patrick Marcellin, E. Jenny Heathcote,

Similar presentations

Ads by Google